The association between neutropenia and risk of bacteremia in patients with human immunodeficiency virus (HIV) infection has been examined in a number of retrospective studies that varied in design and conclusions. Moore et al. (1) , using a matched cohort design, demonstrated that the adjusted relative risk for a combined "serious bacterial infection" endpoint was 7.92 (95 percent confidence interval (CI) 1.18-53.2) for patients with an absolute neutrophil count (ANC) of less than 500//il vs. 500//il or more, with an absolute rate of three to five infections per 100 personmonths of neutropenia. This study lacked power to detect a specific association of neutropenia with bacteremic infections. In a case-control design, Tumbarello et al. (2) demonstrated that neutropenia (<l,000//il vs. >l,000//il) was a positive risk factor for bacteremia in a model that simultaneously controlled for low CD4+ lymphocyte count and use of central venous catheters. Using a hybrid epidemiologic design, Keiser et al. (3) found that the relative risk of bacteremia was 14.9 (p = 0.0027) for patients with ANC < l,000//xl compared with those with ANC 1000//xl or more in analyses matched on age, sex, CD4+ lymphocyte count, and period of entry. The absolute rate of bacteremia in the neutropenic group was 12.6 per 100 patient-months compared with 0.87 per 100 patient-months for the nonneutropenic group. In a pathogen-specific analysis, Weinke et al. (4) reported an association between simultaneous nasopharyngeal colonization with Staphylococcus aureus and neutropenia (ANC < l,000//xl) and septicemia due to 5. aureus. Gilbert et al. (5) found that neutropenia (ANC < 500/JLLI) was a positive risk factor for Pseudomonas aeruginosa bacteremia, as was the presence of a central venous catheter. Finally, in a report using hospitalization for serious bacterial infection (including bacteremia) as the endpoint, Jacobson et al. demonstrated a "continuous, exponential, inverse relation between the incidence of hospitalization for serious bacterial infection and ANC stratum" (6, p. 231) .
Not all studies, however, have found a specific association between neutropenia and bacteremia risk.
Piliero et al. (7) , using a neutrophil threshold of 500/ ixl, concluded that "neutropenic HFV-infected patients do not appear to be at increased risk of bacteremia compared to non-neutropenic HTV-infected patients" (7, p. 78 ) and "do not warrant empiric antibiotic therapy in the absence of an identifiable source" (7, p. 78). Farber et al. (8) , comparing time with ANC >l,000//xl to time with ANC < 1,000//J,1, reported identical rates of "nonopportunistic" infections (1.3 per 1,000/days) for 30 patients with acquired immunodeficiency syndrome and CD4+ lymphocyte counts less than 200/jul
In a retrospective cohort study of 1,645 patients contributing 26,785 patient-weeks of follow-up, we demonstrated a "dose-response" relation between ANC (coded as five ordinal strata with reference category < l,000//xl) and rates of bacteremia due to three gramnegative rods (9) . In that study, the unadjusted rate ratio for a one-category decline in ANC stratum was 3.4, 16.7, and 10.4 for Escherichia coli, Klebsiella pneumoniae, and P. aeruginosa, respectively. In contrast, neutropenia did not appear to be a risk factor for bacteremia due to other gram-negative rods, grampositive cocci including 5. aureus, or gram-positive rods. The purpose of our study was to explore further the association between neutropenia and bacteremia due to E. coli, K. pneumoniae, and P. aeruginosa. We used a nested case-control design and controlled for possible confounding of the neutropenia effect by known or suspected risk factors for bacteremia, including HTV disease stage and use of central venous catheters, injection drugs, cytokines, and prior antimicrobials.
MATERIALS AND METHODS
The cohort study population included 1,645 HTVinfected adult patients aged 15 years or more who received medical care at University of California, San Diego, Medical Center at any time during the study period (September 14, 1991 to June 30,1995) and who also met the following criteria: two or more encounters in the administrative database of the medical center with at least 30 days follow-up between the first and last encounters, and at least one complete blood count with differential during the study period. The case definition specified incident bacteremia during the study period due to E. coli, P. aeruginosa, or K. pneumoniae; confirmation by medical record review; and expert clinical judgment that the bacteremia was not due to in vitro contamination of blood cultures. Recurrent bacteremias during the study period due to any of these three organisms were excluded from analysis in the case-control study.
Controls were selected from the cohort using riskset sampling (10) . Control selection was a four-step process: 1) identification of cohort members who were under care at the study institution on the index date of bacteremia for each case {potential controls); 2) subsetting those potential controls who had at least one ANC determination during the 2-week antecedent risk period of a given case {eligible controls); 3) identification of those eligible controls who met matching criteria {matched eligible controls); and 4) random selection of six matched eligible controls for each case {sampled controls). The procedures for control selection resulted in six controls who were individually matched to each case on week of diagnosis of each case and the availability of ANC data in each of the 2 weeks before diagnosis.
The strategy of risk-set sampling allows for cohort members who have not yet developed the outcome to be selected as controls, even though they may subsequently develop the outcome and then appear in the case series. However, once a patient develops clinical bacteremia due to one of the three index organisms, that patient cannot be selected as a control for subsequent cases. To account for a potential latent period between the first occurrence of bacteremia and clinical diagnosis, if a potential control developed bacteremia due to any of the three index organisms within 30 days after the index date of another antecedent case, that patient was then excluded from the risk set for that antecedent case. Eligibility to contribute to the control series was independent of the possible occurrence of bacteremia due to organisms other than the three index gram-negative rods.
We did not have information in our administrative or clinical databases regarding which of the eligible controls had a central venous catheter, a known risk factor for bacteremia. Since the purpose of the study was to control for confounders of the neutropeniabacteremia association, we hoped to match on the presence of central venous catheters. Patients with central venous catheters typically have blood drawn weekly in the study center. Thus, frequency of ANC ascertainment would likely serve as a partial proxy for the presence of a central venous catheter and could be used as a matching variable. Therefore, the risk set of eligible controls for each case was restricted to subjects for whom ANC measurements were available during the 14 days prior to the index date of bacteremia. Matching on the availability of ANC measurements was operationally defined by partitioning the 14-day period before the index date of bacteremia into two consecutive 7-day intervals, determining if the case had one or more ANC determinations during each of the preceding 7-day intervals, and restricting potential controls for each case to those patients who also had at least one ANC determination during the same Am J Epidemiol Vol. 148, No. 12, 1998 7-day interval as the case. For example, if a case had at least one ANC measurement during the 7 days immediately preceding the index date of bacteremia (days 0 through -6) but none during the 7 days before that (days -7 through -13), then the risk set of matched eligible controls for that case would also have had ANC measurements during the interval of days 0 through -6, but none during the interval of days -7 through -13. For each case, six controls were randomly selected from the corresponding set of matched eligible controls.
The primary exposure variable was mean ANC during the 7-day interval preceding the index date of bacteremia. Although originally measured as a continuous variable, for analytic purposes, ANC was dichotomized as 500/JLLI or less (exposed) versus more than 500//A1 (unexposed). Covariates were ascertained by structured medical record review by one of the investigators (W. C. M.). Covariates included the following measures: 1) presence of an indwelling vascular device during the 14-day risk period (days 0 through -13); 2) mucocutaneous ulceration; 3) history of parenteral drug abuse; 4) recent parenteral drug abuse (within 30 days of the index date); 5) white cell cytokine (granulocyte colony-stimulating factor or granulocyte macrophage-stimulating factor) support during the 14-day risk period; 6) myelosuppressive cancer chemotherapy within 30 days prior to the index date; 7) other myelosuppressive drugs (e.g., zidovudine, ganciclovir, pyrimethamine, high-dose cotrimoxazole, flucytosine, and trimetrexate) during the 14-day risk period; 8) systemic corticosteroid use during the 14-day risk period; 9) prior or concurrent Centers for Disease Control and Prevention category C opportunistic diseases (11, 12) ; 10) most recent absolute CD4 count; and 11) antimicrobial use during the 14-day risk period. Antimicrobials were categorized into nine groups according to class and spectrum of antimicrobial activity. All covariates were modeled as dichotomous variables unless otherwise specified. Continuous covariates (age and absolute CD4 lymphocyte count) were dichotomized at the median values of the entire study group.
Conditional logistic regression (STATA version 4, Stata Corporation, College Station, Texas) was used to model the relations among the exposure variable (neutropenia) and covariates as predictors of bacteremia due to the index organisms. First, the modeling strategy estimated the common odds ratios for neutropenia and the covariates, controlling for the matching variables (time and frequency of ANC ascertainment). Second, to explore the impact of single covariate adjustment on the magnitude of odds ratios for neutropenia, logistic models were fit with predictor terms for neutropenia and for each of the measured covariates taken one at a time. Finally, to control simultaneously for factors known or suspected to be risk factors for the outcome, logistic regression models were fit with predictor terms for neutropenia, HTV disease stage, presence of a vascular device, recent parenteral drug abuse, glucocorticoid use, and those additional covariates observed to be associated with the outcome in unadjusted analyses (p < 0.15).
To detect a dose-response effect for neutropenia, the final multiple logistic model was fit with alternative specification of neutropenia by using interval coding of ANC. The coding schema partitioned ANC values into three strata (0-500, 501-1,000, and >l,000//xl), took the reference category to be ANC of more than l,000//xl, and compared the 0-500/jul and 501-l,000//xl strata with the reference category by using binary coding.
Because the primary exposure variable, ANC, was ascertained on the entire cohort (covariate information being ascertained only on a sample or control group), supplementary analyses were conducted using the entire cohort to explore three potential threats to the validity of inference: 1) the effect of the matching criteria on the magnitude of the effect of neutropenia; 2) the extent to which temporal ambiguity might confound the observed association between neutropenia during the antecedent 7 days (including the index date) and bacteremia; and 3) the effect of missing ANC exposure data among the cases during the 7-day interval preceding the index date of bacteremia.
RESULTS
In the cohort study, 47 episodes of clinical bacteremia due to the index organisms (E. coli, P. aeruginosa, or K. pneumoniae) were observed. Of these 47 cases, two were excluded from the case-control study because they represented recurrent episodes within the study period due to the same organism. Of the remaining 45 cases, one additional case was excluded because no exposure information (i.e., ANC) was recorded during the 14 days antecedent to the index date of bacteremia. By organism type, the distribution of the 44 incident bacteremias comprising the case series was: E. coli, 15 (34 percent); P. aeruginosa, 19 (43 percent); K. pneumoniae, nine (21 percent); and polymicrobial (P. aeruginosa plus K. pneumoniae), one (2 percent).
The median number of potential controls for each case was 625 and varied from 353 to 669. After the imposition of the restriction that controls must have had at least one ANC determination during the 2-week risk period, the median number of eligible controls per case was 214 and varied from 162 to 255. The median Table continues proportion of potential controls who were eligible to serve in a risk set was 0.35 and varied from 0.29 to 0.55. After the imposition of the matching criterion that controls must have ANC ascertainment during the same previous 2 weeks as their case, the median number of matched eligible controls per case was 62 and varied from 39 to 96. The corresponding median proportion of potential controls who were both eligible and met matching criteria was 0.10 (range, 0.07-0.19). Six controls were randomly selected from the corresponding eligible risk sets of each case. Of the 264 controls initially selected, nine (3.4 percent) were replaced because medical records could not be found. These excluded controls did not differ (p > 0.10) from those whose medical records were located by any * ANC, absolute neutrophil count; CDC, Centers for Disease Control and Prevention; AIDS, acquired immunodeficiency syndrome; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor. of the following characteristics: mean ANC (weeks -1 and -2, separately), age, race/ethnicity, or gender. The median age of the study sample was 37 years (range, 21-69). The median absolute CD4+ lymphocyte count was 30//nl (range, 0-762//xl). 
4).
The magnitudes of unadjusted associations between covariates and disease status, in general, were modest. Point estimates of the matched odds ratios were greater than two (suggesting a positive risk factor) or less than 0.5 (suggesting a protective risk factor) for four covariates: recent parenteral drug abuse (odds ratio = 2.70, 95 percent CI 0.67-10.93), myelosuppressive drug use other than cancer chemotherapy (odds ratio = 0.47, 95 percent CI 0.24-0.92), tetracycline use within 14 days prior to the index date (odds ratio = 12.0, 95 percent CI 1.09-132.34), and rifamycin use within 14 days prior to the index date (odds ratio = 0.32, 95 percent CI 0.09-1.09). Table 2 presents the results of conditional logistic regression estimates of the association between neutropenia during the 7-day interval preceding the index date of bacteremia and bacteremia, adjusting in separate models for the effects of covariates taken one at a time. These results demonstrate a consistent effect for neutropenia. Compared with the unadjusted effect of neutropenia (odds ratio = 9.1, 95 percent CI 2.1-38.4), the adjusted odds ratio for neutropenia varied from 6.7 (adjusting for absolute CD4 lymphocyte count, p = 0.013) to 12.6 (adjusting for antecedent rifamycin use, p = 0.002).
To control simultaneously for potential confounders of the neutropenia effect, a multiple logistic model was fit, including predictors known or suspected to be risk factors for bacteremia, i.e., HIV disease stage (absolute CD4 lymphocyte count and history of prior Centers for Disease Control and Prevention acquired immunodeficiency syndrome indicator diagnoses), presence of a vascular device, recent parenteral drug abuse, and systemic glucocorticoid use. In addition, those two covariates (tetracycline and rifamycin use) with associations with the outcome in unadjusted analyses were included in the final model presented in table 3. After simultaneous control for these factors, the association between neutropenia and gramnegative rod bacteremia persisted and was similar to the unadjusted association; the adjusted odds ratio was 8.1 (95 percent CI 1.5-43.1).
The model presented in table 3 was reestimated using interval coding of the ANC exposure variable (0-500, 501-1,000, and >1,000/JU,1). The adjusted effect of neutropenia remains (p= 0.02) and confirms the "dose-response effect" observed in the cohort study. Compared with the reference category (mean ANC, >l,000//xl), the adjusted rate ratio for mean ANC 500-l,000//xl was 2.1 (95 percent CI 0.75-6.11), and for mean ANC 0-500//A1 was 8.8 (95 percent CI 1.64-47.13).
To explore whether matching on the availability of ANC data introduced selection bias in estimating the unadjusted effect of neutropenia, a conditional logistic model was fit to the data that included all eligible controls (i.e., those cohort members who had at least one ANC determination during the 2-week risk period), whether or not they had ANC ascertainment during the same risk period weeks as did their matched cases. The unrestricted cohort (including cases and all eligible controls) included 9,522 patient-14-day intervals. After the matching restriction was imposed, the cohort contained 2,916 patient-14-day intervals. The odds ratio for the estimated effect of low ANC (mean ANC <500 vs. >500//xl in days 0 through -6) was similar to the odds ratio estimated on the matched analysis of the unrestricted cohort, i.e., 10.35 (95 percent CI 4.00-26.79) unmatched compared with 11.37 (95 percent CI 4.21-30.71) (matched).
To understand how much of the observed effect of neutropenia during the first 7 days (week "-1") depended on the day 0 ANC, we reestimated the unadjusted conditional regression model using all eligible control person-time after excluding case-control sets whose case had ANC measurement only on day 0. Of the 44 cases, 16 (36.4 percent) had ANC measurements between days 0 and -6 only on day 0, the index date of bacteremia. If these "day 0 only" cases and their control sets were excluded from analysis, the unadjusted effect of neutropenia for week -1 dropped to 3.08 (95 percent CI 0.41-22.96), which was estimated from the unmatched cohort data (n = 9,522).
A sensitivity analysis was conducted to assess the impact on the estimated odds ratio of missing ANC exposure information in the case series. This analysis included all 44 cases and their eligible controls and was conducted for missing ANC data during the 7 days preceding the index date of bacteremia. During week -1, there were 6,078 eligible control-weeks with ANC exposure information. The observed prevalence of neutropenia among controls was 1.22 percent. In contrast, the observed prevalence of neutropenia among cases was 11.6 percent (five of 43) in week -1. For week -1, only one case lacked exposure information. If that case had been exposed (ANC = 500/jul), the estimated odds ratio would have been 12.81 (95 percent CI 5.39-30.50); if that case had been unexposed (ANC > 500/JU,1), the estimated odds ratio would have been 10.41 (95 percent CI 4.12-26.34). Thus, the impact of missing data during the 7 days preceding the index date was minimal.
DISCUSSION
The association observed in the parent cohort study between neutropenia and rates of bacteremia due to E. coli, K. pneumoniae, or P. aeruginosa has been sub- 500/jiil. When the same factors were controlled for but the alternative interval coding of ANC exposure was used (three mean ANC strata; reference category, >l,000//xl), the dose-response effect of neutropenia observed in the cohort study was also demonstrated in the case-control analysis.
Although neutropenia is clearly a risk factor for gram-negative bacteremia, it is important to note that this outcome occurred frequently (38 of 43 (88 percent of cases)) in the absence of neutropenia during the week preceding documentation of bacteremia.
Supplementary analyses attempted to clarify potential study limitations. By matching on ascertainment of ANC during each of the 2 weeks prior to the index date of bacteremia, we attempted to control for the effect of central venous catheters. In fact, the prevalence of central venous catheters was quite similar among cases and their matched controls. This probably accounted for the failure of catheters to emerge as a predictor of bacteremia in the adjusted analyses. The similarity of unadjusted odds ratios for neutropenia in unmatched analyses, when the matched eligible controls or all eligible controls were used, suggests that matching did not introduce bias in ascertainment of the effect of neutropenia.
In analyses not reported here (Mathews et al., unpublished data), the effect of neutropenia during the interval from days -7 through -13 prior to the index date of bacteremia was examined and, surprisingly, not detected. Failure to observe an association between neutropenia during week -2 and the outcome was unanticipated because previous research had demonstrated that both the absolute neutrophil nadir and the duration of time with neutropenia contributed to risk of bacteremia (13) . Supplementary analyses suggest that ascertainment bias could well have accounted for failure to observe the anticipated effect for neutropenia during week -2.
Because we used risk-set sampling of controls, the odds ratios estimated in this study are estimates of incidence density or rate ratios in the source population in the absence of bias or confounding. However, to interpret the odds ratios as causal parameters requires that there be no temporal ambiguity in the relation between neutropenia and bacteremia. While neutropenia has been established as a risk factor for infection (13) , in the case of bacteremia due to gramnegative bacilli, release of endotoxin has been repeatedly shown to produce a transient dose-related neutropenia as a result of cell margination and sequestration followed in a few hours by neutrophilia (14) (15) (16) . The operational definition of neutropenia used in this study summarized ANC as the arithmetic mean of measured ANC values during the 7-day interval preceding the index date of bacteremia. Including the index date of bacteremia in the calculation of mean ANC for week -1 allows for some temporal ambiguity, particularly for cases whose only ANC value during that week was on the index date. In this study, 16 (36.4 percent) of the cases had ANC determinations during week -1 only on the index date of bacteremia. When these cases and their respective controls were removed, the estimated unadjusted odds ratio for neutropenia during week -1 fell substantially. However, dropping these cases increases the likelihood of ascertainment bias, and resolution of this dilemma must rely on knowledge outside the study. Given the prior evidence that neutropenia is an important risk factor for gramnegative bacteremia in other populations and since a dose-response relation between neutropenia and risk of bacteremia would be unlikely to be observed as consequence of release of endotoxin after the estab-lishment of bacteremia, we feel that the observed association is causal.
The body of accumulating evidence cited above, along with the pathogen-specific associations demonstrated in this study and its parent cohort study, lend strong support to the hypothesis that neutropenia is indeed an important risk factor for gram-negative rod bacteremia. The magnitude of the effect is clinically significant and potentially modifiable by stopping myelosuppressive treatments or using cytokines to prevent or minimize neutropenia.
